Impact of HIV infection, immune status, and integrase inhibitor-based antiretroviral therapy on the gut microbiota in men who have sex with men with and without HIV
HIV infection and antiretroviral therapy (ART) influence gut microbiota, affecting immune function and systemic inflammation. However, isolating the effects of integrase strand transfer inhibitor (INSTI)-based ART on gut microbiota is challenging due to confounding by HIV status, immunosuppression, and behavioral factors. We examined three cohorts of men who have sex with men (MSM) (n = 62): (1) HIV-negative individuals using post-exposure prophylaxis (PEP) (n = 22), (2) people with HIV (PWH) with < 350 CD4 cells/µL sampled before and 48 weeks after ART initiation (n = 23), (3) PWH on long-term INSTI-based ART with immune recovery (n = 17). Fecal samples were collected longitudinally in cohorts 1 (at baseline and after 4 weeks of PEP) and 2 (at baseline and 48 weeks after ART initiation), and at a single timepoint in cohort 3. Microbiota composition was analyzed by 16 S rRNA sequencing, and functional profiling inferred with PICRUSt2. Differential abundance was assessed using ANCOM-BC2. HIV-negative participants showed significantly lower alpha diversity than PWH, and beta diversity differed by HIV status. Short-term INSTI-based ART in PEP users was associated with limited microbiota changes. Pro-inflammatory taxa, such as Prevotellaceae , were enriched in PWH. Functional predictions indicated enrichment of pathways related to cell envelope structure, membrane transport, and stress response. Long-term ART was associated with modest taxonomic and functional shifts, including enrichment of Barnesiella in individuals with immune recovery (ANCOM-BC2, LFC = 3.6, adjusted p = 0.02). HIV infection and immune suppression are the main drivers of gut microbiota alterations in MSM, whereas INSTI-based ART is associated with comparatively modest changes. These findings support a limited impact of INSTI-based ART on microbiota composition and function.
Authors
- Matilde Sánchez‐Conde (ORCID: https://orcid.org/0000-0003-3880-199X)
- Elena Moreno (ORCID: https://orcid.org/0000-0002-2301-4558)
- Marta Sanz (ORCID: https://orcid.org/0000-0002-3252-9748)
- Marta Rosas Cancio-Suárez (ORCID: https://orcid.org/0000-0001-7113-2471)
- Jorge Díaz-Álvarez (ORCID: https://orcid.org/0000-0002-9017-1174)
- Sergio Serrano‐Villar (ORCID: https://orcid.org/0000-0002-5447-3554)
- Clara Crespillo‐Andújar (ORCID: https://orcid.org/0000-0002-1226-8616)
- C. Vanesa Díaz-García (ORCID: https://orcid.org/0000-0001-7570-7113)
- Raquel Ron (ORCID: https://orcid.org/0000-0002-3439-8438)
- Santiago Moreno (ORCID: https://orcid.org/0000-0002-2843-1094)
- Alejandro García García (ORCID: https://orcid.org/0000-0003-4896-6528)
- María Fons-Contreras
Institutions
- Universitat Oberta de Catalunya (ES)
- Universidad de Alcalá (ES)
- Instituto Cajal (ES)
- Instituto de Salud Carlos III (ES)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- Hospital Universitario Ramón y Cajal (ES)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1038/s41598-026-78164-3
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministerio de Ciencia e Innovación
- Instituto de Salud Carlos III
- NextGenerationEU